We report the first case of recurrent sarcoidosis manifested by clinical symptoms, radiographic abnormalities, and pathologic changes in a patient following sequential double allogeneic lung transplantation. A 40-year-old male patient underwent bilateral allogeneic lung transplantation for end-stage pulmonary sarcoidosis. Thirteen months posttransplantation, he developed fatigue, shortness of breath, and bilateral upper lobe pulmonary infiltrates. Transbronchial biopsy specimens revealed noncaseating granulomata. The patient's symptoms and radiographic abnormalities resolved with an increased dose of oral prednisone. (Chest 1994; 106:1597-99) BLT=bilateral lung transplantation; IL-2=interleukin 2
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BLT=bilateral lung transplantation; IL-2=interleukin 2 Aliogeneic lung or heart-lung transplantation has been successfully performed for refractory cases of pulmonary sarcoidosis with respiratory failure. 14 Since sarcoidosis is a disease characterized by an augmented immune response, with activated lymphocytes and mononuclear phagocytes at sites of disease activity,5 the potential for recurrent disease in lung allografts is plausible. Limited data are available regarding long-term survival, the incidence of allograft rejection or other complications, and the rate of recurrent granulomatous disease in the lung allografts. Recent preliminary reports suggest that noncaseating granulomata can be seen in the lung and heart allograft early after transplantation."3 Despite these findings, clinical symptoms and radiographic abnormalities associated with these histologic granulomatous lesions have not been reported previously (to our knowledge). We describe the first case of a patient with symptoms, radiographs, and pathologic changes indicative of recurrent sarcoidosis following bilateral allogeneic lung transplantation. In January 1993, 13 months after BLT, the patient complained of fatigue and shortness of breath. Chest radiographs revealed bilateral upper lobe miliary infiltrates (Fig 1) . High-resolution computed tomographic scans of the lungs confirmed the predominantly upper lobe micronodular infiltration (Fig 2) . Bronchoscopy with transbronchial biopsy specimens revealed noncaseating granulomatous inflammation consistent with sarcoidosis ( Fig 3) . All stains and cultures were negative for fungal, viral, tuberculous, and other bacterial infections. Treatment with oral corticosteroids was increased with prompt resolution of the radiographic abnormalities and symptoms. Despite this, follow-up transbronchial biopsy specimens 6 weeks after initiation of therapy revealed persistence of noncaseating granulomata. Subsequent specimens from transbronchial biopsies performed at 3, 6, and 9 months have revealed persistent noncaseating granulomas. Not withstanding these histologic abnormalities, the patient remains clinically asymptomatic with normal chest radiographs and stable pulmonary function. transplantation, Stewart3 alluded to the fact that noncaseating granulomas have been noted in transbronchial lung biopsy specimens as early as 3 months following heart-lung transplantation for sarcoidosis. However, no specific data were provided and nothing was stated regarding the presence or absence of clinical signs or symptoms. We have also performed combined heart-lung transplantation in a 43-year-old woman with end-stage pulmonary sarcoidosis complicated by severe pulmonary hypertension. Noncaseating granulomata were noted in the lung allografts as early as 3 months posttransplantation, and were seen on each of 3 subsequent serial transbronchial biopsy specimens over a period of 9 months. Despite these histologic findings, she has remained clinically well, with no radiographic or physiologic evidence of disease recurrence.
CASE REPORT
Importantly, we have performed more than 200 transbronchial lung biopsies in 42 patients who have undergone single or double lung transplantation for disorders other than sarcoidosis. Foreign body granulomas were observed in only one patient who experienced repetitive aspiration due to vocal cord paralysis. Granulomas were not observed in any other lung transplant recipient. On the basis of our experience and that of others,' histologic evidence for noncaseating granulomata appears to be common following lung transplantation for sarcoidosis. Clinical disease due to recurrent sarcoidosis appears rare, with our patient being the first well-described case. In our patient, disease recurrence responded to intensification of immunosuppressive therapy. Prednisone, azathioprine, and cyclosporine, agents used to prevent allograft rejection, may ablate the inflammatory response, which may limit or prevent clinically significant sarcoid lesions from developing.
In addition to the potential for recurrence of sarcoidosis in lung allografts, Johnson and coworkers' noted a greater mean severity score for acute rejection during the first 3 months after transplantation compared with 44 contemporaneous, nonsarcoid transplant recipients. This may be extremely important since it is speculated that severe early acute rejection as well as recurrent bouts of rejection and infection may lead to a higher rate of development of irreversible bronchiolitis obliterans. However, one patient at 3 months posttransplant developed optic neuritis secondary to sarcoidosis which responded to high-dose prednisone therapy.7 Recurrence of disease can therefore be seen, albeit rarely. Long-term follow-up is scanty.
In summary, recurrent sarcoid-like granulomata were observed in the lung allografts in both of our patients with sarcoidosis following lung transplantation. However, only one patient had clinical symptoms and radiographic abnormalities associated with these histologic lesions. To our knowledge, our case is the first report of recurrence of clinical symptoms and radiographic changes of sarcoidosis following lung transplantation. Prompt clinical and radiographic improvement was noted following intensification of corticosteroid therapy. On the basis of our experience and that of others,' we believe that lung transplantation remains the only viable life-saving option for patients with end-stage sarcoidosis. However, close clinical, radiographic, and histologic follow-up will be imperative to determine the ultimate efficacy of lung transplantation for patients with end-stage sarcoidosis.
